皮肤肿瘤中的液体活检:当前实践与未来方向
本文综述了循环肿瘤液体活检在皮肤肿瘤中的应用现状与前景。液体活检可对肿瘤状态进行敏感且特异的分析,为组织活检提供无创替代方案,用于实时监测、指导靶向治疗、预测治疗反应及评估耐药与残留病灶。FDA已批准多种检测血浆游离DNA基因改变的试剂盒作为特定分子靶向治疗的伴随诊断,为未来用于早期复发检测及纳入侵袭性皮肤恶性肿瘤标准治疗奠定基础。
要点
- 液体活检可无创替代组织活检,用于皮肤肿瘤实时监测与靶向治疗指导。
- FDA已批准血浆游离DNA检测作为特定靶向治疗的伴随诊断。
- 皮肤科医生需掌握液体活检技术及其在皮肤恶性肿瘤管理中的意义。
核心结论
- 液体活检工具预计将很快整合到不断发展的标准治疗中,以改善侵袭性皮肤恶性肿瘤患者的管理。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 液体活检可对肿瘤状态进行敏感且特异的分析,实现无创实时监测、指导靶向治疗、预测治疗反应及评估耐药与残留病灶。
- FDA已批准多种检测血浆游离DNA基因改变的试剂盒,作为与特定分子靶向治疗匹配的伴随诊断。
临床怎么用
- 皮肤科界需具备液体活检技术及其与皮肤恶性肿瘤管理相关性的实用知识。
局限性
- 原文未报告综述的检索范围及纳入标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decade, the development and implementation of novel circulating tumor "liquid biopsies" in clinical practice has revolutionized cancer care. These tools provide sensitive and specific analysis of tumor status which enable non-invasive alternatives to tissue biopsy for real-time tumor monitoring, guided targeted therapy, predicted treatment response, and assessing therapeutic resistance and residual disease. The FDA has already approved several assays to detect genetic alterations in plasma cell-free DNA for use as companion diagnostics matched to specific molecularly targeted therapies for cancer, setting the stage for future use in early relapse detection and additional applications which are expected to be incorporated into standard-of-care practices for aggressive cutaneous malignancies. It will therefore be important for the dermatology community to have a working knowledge of liquid biopsy techniques and their relevance to the management of cutaneous malignancies. This review highlights state-of-the-art liquid biopsy tools currently in practice with an emphasis on the development and implementation of circulating biomarkers in skin cancers. It is anticipated that liquid biopsy tools will soon become integrated into evolving standards-of-care for improved management of patients with aggressive cutaneous malignancies.
引用
- Choudhury S, Adelaja AO, Neff HA, et al. Liquid biopsy in cutaneous oncology: Current practice and future directions. J Am Acad Dermatol. 2026. PMID: 42413779. doi:10.1016/j.jaad.2026.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。